Acquisition by Janus Henderson Group Plc of 33500 shares of ARCA Biopharma at 3.4647 subject to Rule 16b-3
About 67% of ARCA Biopharma's investor base is looking to short. The analysis of current outlook of investing in ARCA Biopharma suggests that many traders are alarmed regarding ARCA Biopharma's prospects. ARCA Biopharma's investing sentiment overview a quick insight into current market opportunities from investing in ARCA Biopharma. Many technical investors use ARCA Biopharma stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
ARCA |
Filed transaction by ARCA Biopharma 10 Percent Owner. Grant, award or other acquisition pursuant to Rule 16b-3(d)
Read at macroaxis.com
ARCA Biopharma Fundamental Analysis
We analyze ARCA Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ARCA Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ARCA Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Liabilities
Current Liabilities Comparative Analysis
ARCA Biopharma is currently under evaluation in current liabilities category among its peers. Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
ARCA Biopharma Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with ARCA Biopharma stock to make a market-neutral strategy. Peer analysis of ARCA Biopharma could also be used in its relative valuation, which is a method of valuing ARCA Biopharma by comparing valuation metrics with similar companies.
Peers
ARCA Biopharma Related Equities
TPST | Tempest Therapeutics | 21.13 | ||||
RNXT | RenovoRx | 3.20 | ||||
INDP | Indaptus Therapeutics | 2.16 | ||||
SPRO | Spero Therapeutics | 1.90 | ||||
FBRX | Forte Biosciences | 1.86 | ||||
AVTE | Aerovate Therapeutics | 1.56 | ||||
TIL | Instil Bio | 0.78 | ||||
RZLT | Rezolute | 0.68 | ||||
CTMX | CytomX Therapeutics | 1.83 | ||||
ANTX | AN2 Therapeutics | 2.86 | ||||
KTTA | Pasithea Therapeutics | 3.01 | ||||
ADAG | Adagene | 5.37 | ||||
ACRV | Acrivon Therapeutics, | 8.64 | ||||
NXTC | NextCure | 10.52 | ||||
QNRX | Quoin Pharmaceuticals | 14.89 |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Other Consideration for investing in ARCA Stock
If you are still planning to invest in ARCA Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ARCA Biopharma's history and understand the potential risks before investing.
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Transaction History View history of all your transactions and understand their impact on performance | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing |